PrecisionMedicine

A new study sponsored by Sartorius, a global leader in biopharmaceutical innovation, has demonstrated promising advancements in optimizing mRNA transfection in human T-cells using high-throughput cytometry and live-cell imaging. By utilizing jetMESSENGER®, a non-viral mRNA transfection reagent, and leveraging state-of-the-art platforms like the Incucyte® Live-Cell Analysis System and iQue® High-Throughput Screening cytometer, Sartorius researchers have identified enhanced workflows that preserve T-cell viability, improve transfection efficiency, and amplify cytotoxic activity against cancer cells.

Researchers at the University of Turku have identified a novel biomarker that may revolutionize how clinicians assess the progression and severity of multiple sclerosis (MS), a chronic autoimmune disease of the central nervous system. The groundbreaking study, published in Nature Medicine, offers promising new directions for both targeted treatment and faster development of therapeutic drugs—particularly for progressive MS, which remains one of the most challenging forms of the disease to treat.

CHICAGO – A groundbreaking clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 has demonstrated that patients with advanced solid tumors experience significantly improved survival outcomes when treatment is tailored using information from both tissue and liquid biopsies. The findings from the phase II, multicenter ROME trial could redefine the approach to precision oncology and patient care.

At the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, researchers from The University of Texas MD Anderson Cancer Center unveiled promising results from several pioneering clinical trials that could redefine treatment paradigms across multiple cancer types. The presentations, covering personalized vaccines, metastasis-directed radiation therapy, and engineered exosome therapeutics, signal major advances in personalized oncology and immunotherapy.